Acrivon Therapeutics price target raised to $22 from $20 at H.C. Wainwright

H.C. Wainwright analyst Emily Bodnar raised the firm’s price target on Acrivon Therapeutics to $22 from $20 and keeps a Buy rating on the shares after the company reported Q1 results and provided corporate updates. The company ended Q1 with $110M in cash and equivalents, notes the firm, which estimates that the company’s pro-forma cash is sufficient to fund operations into the second half of 2026 and cites lower than anticipated operating expenses for the firm’s raised price target.